ECORA RESOURCES PLC — Regulatory Filings 2019

Feb 18, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2878Q

Anglo Pacific Group PLC

18 February 2019

News Release

18 February 2019

Anglo Pacific Group PLC

Appointment of Joint Corporate Broker

Anglo Pacific Group PLC (the "Company") (LSE: APF, TSX: APY), the London and Toronto listed royalty company, is pleased to announce the appointment of Berenberg as the Company's Joint Corporate Broker with immediate effect.

Berenberg will work alongside the Company's Joint Corporate Brokers, BMO Capital Markets Limited and Peel Hunt LLP.

For further information:

Anglo Pacific Group PLC	+44 (0) 20 3435 7400
Julian Treger - Chief Executive Officer
Kevin Flynn - Chief Financial Officer and Company Secretary
Website:	www.anglopacificgroup.com
Berenberg	+44 (0) 20 3207 7800
Matthew Armitt / Detlir Elezi
BMO Capital Markets Limited	+44 (0) 20 7664 8020
Jeffrey Couch / Tom Rider
Peel Hunt LLP	+44 (0) 20 7418 8900
Ross Allister / James Bavister / David McKeown
Capital Markets Communications Limited (Camarco)	+44 (0) 20 3757 4997
Gordon Poole / Owen Roberts / James Crothers

Notes to Editors

About Anglo Pacific

Anglo Pacific Group PLC is a global natural resources royalty and streaming company. The Company's strategy is to develop a leading international diversified royalty and streaming company with a portfolio centred on base metals and bulk materials, focusing on accelerating income growth through acquiring royalties on projects that are currently cash flow generating or are expected to be within the next 24 months, as well as investment in earlier stage royalties. It is a continuing policy of the Company to pay a substantial portion of these royalties to shareholders as dividends. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

APPDGGDDUBBBGCR